AMGN
AMGEN INC
Nasdaq: AMGN · Thousand Oaks, CA · Healthcare
$376.04+4.54 (+1.22%)Closed
Market Cap$202.95B
Cash$12.04Bmost recent
Runwayprofitable
P/E (TTM)26.4EPS $14.23
52-Wk Range$265.40 – $385.25
Avg Volume2.6M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$376.04+19.6%
Pipeline

Drug candidates sponsored by AMGEN · ClinicalTrials.gov

66 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4VIMOVO 250/20
Juvenile Idiopathic Arthritis (JIA)
Completed
2015-02past
1
Phase 4Etanercept
Moderate to Severe Rheumatoid Arthritis+1 more
Completed
2015-06-11past
2
Phase 4darbepoetin alfa
Chronic Kidney Disease+11 more
Completed
2017-06-07past
5
Phase 4Pegloticase
Uncontrolled Gout
Completed
2022-08-23past
1
Phase 4Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Active, not recruiting
2028-06-26
1
Phase 4Aranesp
Anemia
Completed—1
Phase 4Anakinra (r-metHuIL-1ra)
Rheumatoid Arthritis
Completed—1
Phase 3De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease+1 more
Completed
2005-03past
1
Phase 3Epoetin alfa RB
Nephrology
Completed
2007-01past
1
Phase 3MR prednisone
Rheumatoid Arthritis
Completed
2009-05past
1
Phase 3AMG 162
Prostate Cancer+3 more
Completed
2012-02past
2
Phase 3Aeroquin
Cystic Fibrosis
Completed
2012-05-07past
1
Phase 3Cinacalcet
Chronic Allograft Nephropathy+10 more
Completed
2012-09-13past
2
Phase 3cinacalcet capsule
Chronic Kidney Disease+4 more
Terminated
2014-04-30past
1
Phase 3Rilotumumab
Gastric Cancer
Terminated
2015-06past
1
Phase 3Carfilzomib
Multiple Myeloma+6 more
Completed
2016-08past
5
Phase 3Interferon γ-1b
Friedreich's Ataxia
Completed
2017-03-21past
1
Phase 3Placebo
Breast Cancer+1 more
Completed
2017-08-31past
2
Phase 3Evolocumab
Hyperlipidemia+2 more
Completed
2017-12-06past
4
Phase 3Denosumab
Bone Metastases in Men With Hormone-Refractory Prostate Cancer+2 more
Completed
2018-08-10past
2
Phase 3Teprotumumab
Thyroid Eye Disease+2 more
Completed
2020-06-08past
3
Phase 3Apremilast
Palmoplantar Pustulosis+1 more
Completed
2023-08-19past
3
Phase 3Rocatinlimab
Atopic Dermatitis
Completed
2025-05-03past
3
Phase 3ABP 234
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Active, not recruiting
2026-12-14
1
Phase 3Etelcalcetide
Hyperparathyroidism, Secondary+1 more
Recruiting
2027-06-30
2
Phase 3Blinatumomab
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia+2 more
Active, not recruiting
2027-11-24
3
Phase 3Maridebart Cafraglutide
Atherosclerotic Cardiovascular Disease+3 more
Recruiting
2028-06-30
2
Phase 2pegfilgrastim 12 mg
Lymphoma+4 more
Completed
2004-03past
1
Phase 2pegfilgrastim
Sarcoma+1 more
Completed
2007-01past
1
Phase 2AMG 223
End Stage Renal Disease+3 more
Completed
2008-11past
1
Phase 2Apremilast 10mg
Psoriasis+1 more
Completed
2009-08-01past
1
Phase 2Previous denosumab
Low Bone Mass+3 more
Completed
2010-06past
1
Phase 1CCX 354-C
Rheumatoid Arthritis
Completed
2010-07past
1
Phase 2Romosozumab
Postmenopausal Osteoporosis (PMO)
Completed
2014-10-09past
1
Phase 2Abrilumab
Ulcerative Colitis
Completed
2015-07-13past
1
Phase 2AMG 337
Stomach Neoplasms
Terminated
2016-10past
1
Phase 2Erenumab
Stable Angina+2 more
Completed
2017-01-23past
3
Phase 2Talimogene Laherparepvec
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma+2 more
Completed
2019-04-30past
3
Phase 2Avacopan
Hidradenitis Suppurativa+2 more
Completed
2021-01-14past
2
Phase 2VIB4920
Rheumatoid Arthritis
Completed
2021-12-28past
1
Phase 1sotorasib
KRAS p.G12C Mutant Advanced Solid Tumors+2 more
Active, not recruiting
2026-12-17
2
Phase 2Tarlatamab
Extensive Stage Small Cell Lung Cancer+1 more
Active, not recruiting
2029-02-09
2
Phase 2ABX-EGF
Colorectal Cancer
Completed—1
Phase 2Filgrastim
HIV Infections+1 more
Completed—1
Phase 1AMG 623
Systemic Lupus Erythematosus
Completed
2007-04past
1
Phase 1ganitumab
Lymphoma+4 more
Completed
2010-04past
1
Phase 1AMG 557
Systemic Lupus Erythematosus
Completed
2012-05past
2
Phase 1AMG 181
Ulcerative Colitis+1 more
Completed
2014-04past
1
Phase 1[¹⁴C]Etelcalcetide
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Completed
2014-04-15past
1
Phase 1AMG 357
Inflammatory Disease
Completed
2014-09past
1
Phase 1CCX168
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Completed
2016-02-09past
1
Phase 1AMG 986 IV
Heart Failure+1 more
Terminated
2019-04-18past
1
Phase 1AMG 510
Healthy Participants
Completed
2019-11-19past
1
Phase 1Omeprazole
Healthy Volunteers
Completed
2022-09-08past
1
Phase 1TEPEZZA
Diffuse Cutaneous Systemic Sclerosis
Terminated
2022-11-29past
1
Phase 1AMG 176
Relapsed or Refractory Multiple Myeloma+1 more
Terminated
2024-05-27past
1
Phase 1AMG 133 (frozen liquid)
Overweight and Obesity
Completed
2025-05-22past
1
Phase 1AMG 701
Relapsed/Refractory Multiple Myeloma
Withdrawn
2025-08-02past
1
N/ANot applicable- observational study
Birth Defect+2 more
Terminated
2014-01past
1
N/AUnnamed
Anaemia
Completed
2015-04past
1
N/AUnnamed
Solid Tumours+1 more
Completed
2015-05-15past
1
N/ARAYOS (delayed-release prednisone)
Rheumatoid Arthritis
Completed
2015-10past
1
N/AUnnamed
Wild-type RAS Metastatic Colorectal Cancer
Completed
2016-11-30past
1
N/AUnnamed
Atherosclerotic Cardiovascular Disease
Completed
2023-12-30past
1
N/AUnnamed
Blincyto Use in Routine Clinical Practice
Completed
2024-03-20past
1
N/AUnnamed
Major Cardiovascular Event+1 more
Recruiting
2028-12-19
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.